Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 3/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | RHOC | P08134 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | THRB | P10828 | 1/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL7037659 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL5072672 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL7703363 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL3832 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL6064039 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL137842 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL149165 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL663081 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL1031326 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL5077060 | 0.98 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024451-A | Avastine photodegradation impurity and application and preparation method thereof | 重庆医药高等专科学校 | 2021-06-25 | — | — | CN | claimed |
| EP-2043613-A1 | SOLID FORM | FMC CORPORATION (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080311162-A1 | Solid form | FMC CORPORATION | 2008-12-18 | — | — | US | claimed |
| US-20080286343-A1 | Solid form | FMC CORPORATION | 2008-11-20 | — | — | US | claimed |
| WO-2008140460-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008140461-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008140459-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-11-20 | — | — | WO | claimed |
| US-20080286344-A1 | Solid form | FMC CORPORATION | 2008-11-20 | — | — | US | claimed |
| WO-2008008120-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-01-17 | — | — | WO | claimed |
| US-20080014228-A1 | Solid form | FMC CORPORATION | 2008-01-17 | — | — | US | claimed |
| CN-118159294-A | Combination therapy for the treatment of cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-116601171-A | Combination therapy for cancer | 百时美施贵宝公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-113024451-A | Avastine photodegradation impurity and application and preparation method thereof | 重庆医药高等专科学校 | 2021-06-25 | — | — | CN | disclosed |
| CN-113024451-A | Avastine photodegradation impurity and application and preparation method thereof | 重庆医药高等专科学校 | 2021-06-25 | — | — | CN | disclosed |
| US-20200368185-A1 | COMBINATION FORMULATION CONTAINING SUSTAINED RELEASE METFORMIN AND IMMEDIATE RELEASE HMG-COA REDUCTASE INHIBITOR | HK INNO N CORP (KR) | 2020-11-26 | — | — | US | disclosed |
| WO-2008008120-A1 | SOLID FORM | FMC CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080014228-A1 | Solid form | FMC CORPORATION | 2008-01-17 | — | — | US | disclosed |
| US-20060204578-A1 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2006-09-14 | — | — | US | disclosed |
| EP-1461018-A2 | DUAL CONTROLLED RELEASE DOSAGE FORM | Osmotica Corp. (VG) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003039519-A2 | DUAL CONTROLLED RELEASE DOSAGE FORM | OSMOTICA CORP. (VG) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368185-A1 | COMBINATION FORMULATION CONTAINING SUSTAINED RELEASE METFORMIN AND IMMEDIATE RELEASE HMG-COA REDUCTASE INHIBITOR | HMGCR, LDLR, PCSK9 | HMGCR 1/4885ABCB11 232/4885SLCO1B1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.